ArticleBlood advances2026

Ibrutinib or non-BTK inhibitor therapy in relapsed Waldenström macroglobulinemia: a real-life multicenter Italian study.

Francesco Autore et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.